Supplementary Material for: Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in Non-Small Cell Lung Cancer

<b><i>Objective:</i></b> This study was conducted to investigate whether polymorphisms in glycolysis-related genes are associated with clinical outcomes of patients with advanced-stage non-small cell lung cancer (NSCLC) undergoing chemotherapy. <b><i>Methods:</i></b> A total of 377 patients with NSCLC were enrolled. Sixty-five single-nucleotide polymorphisms in 26 genes involved in the glycolytic pathway were evaluated. The associations of the variants with the chemotherapy response and overall survival (OS) were analyzed. <b><i>Results:</i></b> Among the 65 variants investigated, <i>PFKL</i> rs2073436C&gt;G and <i>GPI</i> rs7248411C&gt;G significantly correlated with clinical outcomes after chemotherapy in multivariate analyses. <i>PFKL</i> rs2073436C&gt;G was significantly associated with both a worse response to chemotherapy (adjusted odds ratio [aOR] = 0.64, 95% CI = 0.45–0.90, <i>p</i> = 0.01) and a worse OS (adjusted hazard ratio [aHR] = 1.35, 95% CI = 1.14–1.61, <i>p</i> = 0.001). <i>GPI</i> rs7248411C&gt;G was significantly associated with both a better chemotherapy response (aOR = 1.58, 95% CI = 1.07–2.23, <i>p</i> = 0.02) and a better OS (aHR = 0.80, 95% CI = 0.66–0.98, <i>p</i> = 0.03). When stratified by tumor histology, <i>PFKL</i> rs2073436C&gt;G was significantly associated with OS only in squamous cell carcinoma, whereas <i>GPI</i> rs7248411C&gt;G exhibited a significant association with the chemotherapy response and OS only in adenocarcinoma. <b><i>Conclusion:</i></b> This result suggests that the <i>PFKL</i> rs2073436C&gt;G and <i>GPI</i> rs7248411C&gt;G are useful for predicting the clinical outcome of first-line paclitaxel-cisplatin chemotherapy in NSCLC.